Therapeutic Benefit in Rheumatoid Cachexia Illustrated Using a Novel Primary Human Triple Cell Coculture Model

Background. The loss of muscle mass in rheumatoid arthritis (RA), termed rheumatoid cachexia, is predicted to result from the complex interactions between different cell types involved in the maintenance of skeletal muscle mass, namely, myoblasts, fibroblasts, and macrophages. The complexity within...

Full description

Saved in:
Bibliographic Details
Main Authors: Tracey Ollewagen, Gareth S. Tarr, Kathryn H. Myburgh, Helmuth Reuter, Carine Smith
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:International Journal of Inflammation
Online Access:http://dx.doi.org/10.1155/2022/1524913
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832565795575562240
author Tracey Ollewagen
Gareth S. Tarr
Kathryn H. Myburgh
Helmuth Reuter
Carine Smith
author_facet Tracey Ollewagen
Gareth S. Tarr
Kathryn H. Myburgh
Helmuth Reuter
Carine Smith
author_sort Tracey Ollewagen
collection DOAJ
description Background. The loss of muscle mass in rheumatoid arthritis (RA), termed rheumatoid cachexia, is predicted to result from the complex interactions between different cell types involved in the maintenance of skeletal muscle mass, namely, myoblasts, fibroblasts, and macrophages. The complexity within the muscle is further highlighted by the incidence of nonresponsiveness to current RA treatment strategies. Method. This study aimed at determining differences in the cellular responses in a novel human primary cell triple coculture model exposed to serum collected from nonarthritic controls (NC), RA treatment naïve (RATN), and RA treatment-nonresponding (RATNR) patients. Bone morphogenetic protein-7 (BMP-7) was investigated as a treatment option. Results. Plasma analysis indicated that samples were indeed representative of healthy and RA patients—notably, the RATNR patients additionally exhibited dysregulated IL-6/IL-10 correlations. Coculture exposure to serum from RATNR patients demonstrated increased cellular growth (p<0.001), while both hepatocyte growth factor (p<0.01) and follistatin (p<0.001) were reduced when compared to NC. Furthermore, decreased concentration of markers of extracellular matrix formation, transforming growth factor-β (TGF-β; p<0.05) and fibronectin (p<0.001), but increased collagen IV (p<0.01) was observed following RATNR serum exposure. Under healthy conditions, BMP-7 exhibited potentially beneficial results in reducing fibrosis-generating TGF-β (p<0.05) and fibronectin (p<0.05). BMP-7 further exhibited protective potential in the RA groups through reversing the aberrant tendencies observed especially in the RATNR serum-exposed group. Conclusion. Exposure of the triple coculture to RATN and RATNR serum resulted in dysregulated myoblast proliferation and growth, and ECM impairment, which was reversed by BMP-7 treatment.
format Article
id doaj-art-805d80f5277f451e870427db0629a8a8
institution Kabale University
issn 2042-0099
language English
publishDate 2022-01-01
publisher Wiley
record_format Article
series International Journal of Inflammation
spelling doaj-art-805d80f5277f451e870427db0629a8a82025-02-03T01:06:37ZengWileyInternational Journal of Inflammation2042-00992022-01-01202210.1155/2022/1524913Therapeutic Benefit in Rheumatoid Cachexia Illustrated Using a Novel Primary Human Triple Cell Coculture ModelTracey Ollewagen0Gareth S. Tarr1Kathryn H. Myburgh2Helmuth Reuter3Carine Smith4Dept Physiological SciencesWinelands Rheumatology CentreDept Physiological SciencesWinelands Rheumatology CentreDivision of Clinical PharmacologyBackground. The loss of muscle mass in rheumatoid arthritis (RA), termed rheumatoid cachexia, is predicted to result from the complex interactions between different cell types involved in the maintenance of skeletal muscle mass, namely, myoblasts, fibroblasts, and macrophages. The complexity within the muscle is further highlighted by the incidence of nonresponsiveness to current RA treatment strategies. Method. This study aimed at determining differences in the cellular responses in a novel human primary cell triple coculture model exposed to serum collected from nonarthritic controls (NC), RA treatment naïve (RATN), and RA treatment-nonresponding (RATNR) patients. Bone morphogenetic protein-7 (BMP-7) was investigated as a treatment option. Results. Plasma analysis indicated that samples were indeed representative of healthy and RA patients—notably, the RATNR patients additionally exhibited dysregulated IL-6/IL-10 correlations. Coculture exposure to serum from RATNR patients demonstrated increased cellular growth (p<0.001), while both hepatocyte growth factor (p<0.01) and follistatin (p<0.001) were reduced when compared to NC. Furthermore, decreased concentration of markers of extracellular matrix formation, transforming growth factor-β (TGF-β; p<0.05) and fibronectin (p<0.001), but increased collagen IV (p<0.01) was observed following RATNR serum exposure. Under healthy conditions, BMP-7 exhibited potentially beneficial results in reducing fibrosis-generating TGF-β (p<0.05) and fibronectin (p<0.05). BMP-7 further exhibited protective potential in the RA groups through reversing the aberrant tendencies observed especially in the RATNR serum-exposed group. Conclusion. Exposure of the triple coculture to RATN and RATNR serum resulted in dysregulated myoblast proliferation and growth, and ECM impairment, which was reversed by BMP-7 treatment.http://dx.doi.org/10.1155/2022/1524913
spellingShingle Tracey Ollewagen
Gareth S. Tarr
Kathryn H. Myburgh
Helmuth Reuter
Carine Smith
Therapeutic Benefit in Rheumatoid Cachexia Illustrated Using a Novel Primary Human Triple Cell Coculture Model
International Journal of Inflammation
title Therapeutic Benefit in Rheumatoid Cachexia Illustrated Using a Novel Primary Human Triple Cell Coculture Model
title_full Therapeutic Benefit in Rheumatoid Cachexia Illustrated Using a Novel Primary Human Triple Cell Coculture Model
title_fullStr Therapeutic Benefit in Rheumatoid Cachexia Illustrated Using a Novel Primary Human Triple Cell Coculture Model
title_full_unstemmed Therapeutic Benefit in Rheumatoid Cachexia Illustrated Using a Novel Primary Human Triple Cell Coculture Model
title_short Therapeutic Benefit in Rheumatoid Cachexia Illustrated Using a Novel Primary Human Triple Cell Coculture Model
title_sort therapeutic benefit in rheumatoid cachexia illustrated using a novel primary human triple cell coculture model
url http://dx.doi.org/10.1155/2022/1524913
work_keys_str_mv AT traceyollewagen therapeuticbenefitinrheumatoidcachexiaillustratedusinganovelprimaryhumantriplecellcoculturemodel
AT garethstarr therapeuticbenefitinrheumatoidcachexiaillustratedusinganovelprimaryhumantriplecellcoculturemodel
AT kathrynhmyburgh therapeuticbenefitinrheumatoidcachexiaillustratedusinganovelprimaryhumantriplecellcoculturemodel
AT helmuthreuter therapeuticbenefitinrheumatoidcachexiaillustratedusinganovelprimaryhumantriplecellcoculturemodel
AT carinesmith therapeuticbenefitinrheumatoidcachexiaillustratedusinganovelprimaryhumantriplecellcoculturemodel